Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- China’s Haihe Makes Japan Debut with NDA Filing of Lung Cancer Drug
September 12, 2023
- Sumitomo to Ramp Up Regenerative, Cell Therapy Biz to Counter Latuda Patent Cliff
September 11, 2023
- Otsuka, Shape Link Up on AAV Gene Therapies for Eye Diseases
September 11, 2023
- TA-MUC1-Directed ADC Enters Clinic for Solid Tumors: Daiichi Sankyo
September 11, 2023
- Japan Ethical Drug Sales Up 7.9% in July: Crecon
September 11, 2023
- After Idorsia Deal, Sosei Pivoting to High-Profit Model with In-House Sales System
September 8, 2023
- Astellas Drops IRA Lawsuit after Xtandi Avoids 1st Drug List
September 8, 2023
- Daiichi Sankyo Files XBB.1.5 COVID Jab, Eyes Japan Rollout by Year-End
September 8, 2023
- Maruho Gets Asia Rights to Hyperhidrosis Wipe Drug
September 8, 2023
- Keytuda Filed in Japan in NSCLC Neoadjuvant/Adjuvant Setting: MSD
September 8, 2023
- Brexpiprazole Combo Logs Mixed Results in 2 PTSD Trials: Otsuka/Lundbeck
September 8, 2023
- Noile-Immune Hits Early Milestone for CAR-T Tech Transfer to Chugai
September 7, 2023
- PNH Drug Crovalimab Accepted for FDA Review: Chugai
September 7, 2023
- Daiichi Sankyo’s Omicron-Tailored Booster Hits Main Goal: Japan PIII
September 7, 2023
- Keytruda Nabs Top Slot in Japan Sales Ranking, 1st Time in 2 Years: Encise
September 7, 2023
- BMS Gets Rights to Zenas Antibody in Japan, Korea, and More Regions
September 7, 2023
- Osaka Court Bars Sawai’s Teribone Generic over Manufacturing Patents
September 6, 2023
- Sawai Poised to Respond to Generic System Reform and Raise Productivity: New President
September 5, 2023
- RaQualia’s Acid Reducer Tegoprazan Now Available in Singapore
September 5, 2023
- Nobelpharma Bags UK Approval for Hyftor
September 5, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…